Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries.

Campbell JR, Johnston JC, Cook VJ, Sadatsafavi M, Elwood RK, Marra F.

Emerg Infect Dis. 2019 Apr;25(4):661-671. doi: 10.3201/eid2504.171630.

2.

Extent, trends, and determinants of controller/reliever balance in mild asthma: a 14-year population-based study.

Khakban A, FitzGerald JM, Tavakoli H, Lynd L, Ehteshami-Afshar S, Sadatsafavi M.

Respir Res. 2019 Feb 28;20(1):44. doi: 10.1186/s12931-019-1007-0.

3.

Use of biologics during pregnancy and risk of serious infections in the mother and baby: a Canadian population-based cohort study.

Tsao NW, Lynd LD, Sayre EC, Sadatsafavi M, Hanley G, De Vera MA.

BMJ Open. 2019 Feb 20;9(2):e023714. doi: 10.1136/bmjopen-2018-023714.

4.

Introduction to Precision Medicine in COPD.

Leung JM, Obeidat M, Sadatsafavi M, Sin DD.

Eur Respir J. 2019 Jan 24. pii: 1802460. doi: 10.1183/13993003.02460-2018. [Epub ahead of print]

PMID:
30679189
5.

Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada.

Sadatsafavi M, Ghanbarian S, Adibi A, Johnson K, FitzGerald JM, Flanagan W, Bryan S, Sin D; Canadian Respiratory Research Network.

Med Decis Making. 2019 Feb;39(2):152-167. doi: 10.1177/0272989X18824098. Epub 2019 Jan 24.

PMID:
30678520
6.

Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD.

Johnson KM, Safari A, Tan WC, Bourbeau J, FitzGerald JM, Sadatsafavi M, Study OBOTCCOOLDC; Canadian Respiratory Research Network.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 13;13:3983-3995. doi: 10.2147/COPD.S184424. eCollection 2018.

7.

Making sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economists.

van Boven JFM, van de Hei SJ, Sadatsafavi M.

Eur Respir J. 2019 Mar 7;53(3). pii: 1801816. doi: 10.1183/13993003.01816-2018. Print 2019 Mar. No abstract available.

PMID:
30578398
8.

A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma.

Al Efraij K, Johnson KM, Wiebe D, Sadatsafavi M, FitzGerald JM.

J Asthma. 2018 Dec 4:1-13. doi: 10.1080/02770903.2018.1539100. [Epub ahead of print]

PMID:
30513226
9.

Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study.

Chen W, Johnson KM, FitzGerald JM, Sadatsafavi M, Leslie WD.

Arch Osteoporos. 2018 Oct 29;13(1):116. doi: 10.1007/s11657-018-0537-2.

PMID:
30374631
10.

Screening for Latent Tuberculosis Infection in Migrants With CKD: A Cost-effectiveness Analysis.

Campbell JR, Johnston JC, Ronald LA, Sadatsafavi M, Balshaw RF, Cook VJ, Levin A, Marra F.

Am J Kidney Dis. 2019 Jan;73(1):39-50. doi: 10.1053/j.ajkd.2018.07.014. Epub 2018 Sep 28.

PMID:
30269868
11.

Relative impact characteristic curve: a graphical tool to visualize and quantify the clinical utility and population-level consequences of implementing markers.

Sadatsafavi M, Gustafson P, Zafari Z, Sin DD.

Ann Epidemiol. 2018 Oct;28(10):717-723.e3. doi: 10.1016/j.annepidem.2018.07.014. Epub 2018 Jul 30.

12.

The diagnostic performance of patient symptoms in screening for COPD.

Johnson KM, Tan WC, Bourbeau J, Sin DD, Sadatsafavi M; Canadian Cohort of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network.

Respir Res. 2018 Aug 3;19(1):147. doi: 10.1186/s12931-018-0853-5.

13.

Asthma is not associated with the need for surgery in Crohn's disease when controlling for smoking status: a population-based cohort study.

Kuenzig ME, Sadatsafavi M, Aviña-Zubieta JA, Burne RM, Abrahamowicz M, Beauchamp ME, Kaplan GG, Benchimol EI.

Clin Epidemiol. 2018 Jul 12;10:831-840. doi: 10.2147/CLEP.S156772. eCollection 2018.

14.

Long-Term Trajectories of Mild Asthma in Adulthood and Risk Factors of Progression.

Chen W, FitzGerald JM, Lynd LD, Sin DD, Sadatsafavi M.

J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):2024-2032.e5. doi: 10.1016/j.jaip.2018.04.027. Epub 2018 May 7.

PMID:
29746917
15.

The projected economic and health burden of sub-optimal asthma control in Canada.

Zafari Z, Sadatsafavi M, Chen W, FitzGerald JM.

Respir Med. 2018 May;138:7-12. doi: 10.1016/j.rmed.2018.03.018. Epub 2018 Mar 16.

PMID:
29724396
16.

Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study.

McCormick N, Marra CA, Sadatsafavi M, Aviña-Zubieta JA.

Lupus. 2018 Jul;27(8):1247-1258. doi: 10.1177/0961203318768882. Epub 2018 Apr 17.

PMID:
29665755
17.

Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjögren's Syndrome: A General Population-Based Study.

McCormick N, Marra CA, Sadatsafavi M, Kopec JA, Aviña-Zubieta JA.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):142-154. doi: 10.1002/acr.23573.

PMID:
29648677
18.

The Impact of Care Specialty on Survival-Adjusted Medical Costs of COPD Patients After a Hospitalization: a longitudinal analysis.

Chen W, Sin DD, FitzGerald JM, Sadatsafavi M; Canadian Respiratory Research Network.

J Gen Intern Med. 2018 Sep;33(9):1528-1535. doi: 10.1007/s11606-018-4406-x. Epub 2018 Apr 2.

PMID:
29611088
19.

Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study.

Tsao NW, Sayre EC, Hanley G, Sadatsafavi M, Lynd LD, Marra CA, De Vera MA.

Ann Rheum Dis. 2018 Jun;77(6):869-874. doi: 10.1136/annrheumdis-2018-213023. Epub 2018 Mar 1.

PMID:
29496718
20.

The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.

Johnston JC, van der Kop ML, Smillie K, Ogilvie G, Marra F, Sadatsafavi M, Romanowski K, Budd MA, Hajek J, Cook V, Lester RT.

Eur Respir J. 2018 Feb 7;51(2). pii: 1701488. doi: 10.1183/13993003.01488-2017. Print 2018 Feb.

PMID:
29437940
21.

Predictors of inappropriate and excessive use of reliever medications in asthma: a 16-year population-based study.

Tavakoli H, Mark FitzGerald J, Lynd LD, Sadatsafavi M.

BMC Pulm Med. 2018 Feb 12;18(1):33. doi: 10.1186/s12890-018-0598-4.

22.

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US.

Zafari Z, Sadatsafavi M, Mark FitzGerald J; Canadian Respiratory Research Network.

Cost Eff Resour Alloc. 2018 Jan 30;16:3. doi: 10.1186/s12962-018-0089-8. eCollection 2018.

23.

Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Johnson KM, Bryan S, Ghanbarian S, Sin DD, Sadatsafavi M.

Respir Res. 2018 Feb 7;19(1):26. doi: 10.1186/s12931-018-0731-1. Review.

24.

Response.

Raymakers AJN, Sadatsafavi M, Sin DD, De Vera MA, Lynd LD.

Chest. 2018 Feb;153(2):578-579. doi: 10.1016/j.chest.2017.12.006. No abstract available.

PMID:
29406228
25.

The association between previous and future severe exacerbations of chronic obstructive pulmonary disease: Updating the literature using robust statistical methodology.

Sadatsafavi M, Xie H, Etminan M, Johnson K, FitzGerald JM; Canadian Respiratory Research Network.

PLoS One. 2018 Jan 19;13(1):e0191243. doi: 10.1371/journal.pone.0191243. eCollection 2018.

26.

Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada.

Campbell JR, Johnston JC, Sadatsafavi M, Cook VJ, Elwood RK, Marra F.

PLoS One. 2017 Oct 30;12(10):e0186778. doi: 10.1371/journal.pone.0186778. eCollection 2017.

27.

Risk of Incident Chronic Obstructive Pulmonary Disease in Rheumatoid Arthritis: A Population-Based Cohort Study.

Mcguire K, Aviña-Zubieta JA, Esdaile JM, Sadatsafavi M, Sayre EC, Abrahamowicz M, Lacaille D.

Arthritis Care Res (Hoboken). 2017 Oct 19. doi: 10.1002/acr.23410. [Epub ahead of print]

28.

Plexiform Schwannoma of the Finger: A Case Report and Literature Review.

Mortazavi N, Novin K, Zerehpoosh FB, Sadatsafavi M.

Indian Dermatol Online J. 2017 Sep-Oct;8(5):355-357. doi: 10.4103/idoj.IDOJ_370_16.

29.

Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Population-Based Cohort Study.

Tsao NW, Lynd LD, Sadatsafavi M, Hanley G, De Vera MA.

Arthritis Care Res (Hoboken). 2018 Jul;70(7):979-986. doi: 10.1002/acr.23434. Epub 2018 Apr 30.

PMID:
28973840
30.

The impact of inappropriate use of short acting beta agonists in asthma.

FitzGerald JM, Tavakoli H, Lynd LD, Al Efraij K, Sadatsafavi M.

Respir Med. 2017 Oct;131:135-140. doi: 10.1016/j.rmed.2017.08.014. Epub 2017 Aug 17.

PMID:
28947020
31.

Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study.

Patel AR, Campbell JR, Sadatsafavi M, Marra F, Johnston JC, Smillie K, Lester RT.

BMJ Open. 2017 Sep 15;7(9):e015108. doi: 10.1136/bmjopen-2016-015108.

32.

Do community demographics, environmental characteristics and access to care affect risks of developing ACOS and mortality in people with asthma?

To T, Zhu J, Carlsten C, Larsen K, Ryckman K, Feldman LY, Crighton E, Lougheed MD, Licskai C, Villeneuve PJ, Su Y, Sadatsafavi M, Gershon A; Canadian Respiratory Research Network.

Eur Respir J. 2017 Sep 11;50(3). pii: 1700644. doi: 10.1183/13993003.00644-2017. Print 2017 Sep. No abstract available.

33.

Excess economic burden of comorbidities in COPD: a 15-year population-based study.

Chen W, FitzGerald JM, Sin DD, Sadatsafavi M; Canadian Respiratory Research Network.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700393. doi: 10.1183/13993003.00393-2017. Print 2017 Jul.

34.

Improving precision in the prediction of asthma exacerbations.

FitzGerald JM, Sadatsafavi M.

Lancet Respir Med. 2017 Jul;5(7):539-540. doi: 10.1016/S2213-2600(17)30212-6. Epub 2017 Jun 2. No abstract available.

PMID:
28583394
35.

Stability of Asthma Symptom Control in a Longitudinal Study of Mild-Moderate Asthmatics.

Johnson KM, FitzGerald JM, Tavakoli H, Chen W, Sadatsafavi M.

J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1663-1670.e5. doi: 10.1016/j.jaip.2017.04.006. Epub 2017 May 10.

PMID:
28499773
36.

Asthma Is Associated With Subsequent Development of Inflammatory Bowel Disease: A Population-based Case-Control Study.

Kuenzig ME, Barnabe C, Seow CH, Eksteen B, Negron ME, Rezaie A, Panaccione R, Benchimol EI, Sadatsafavi M, Aviña-Zubieta JA, Kaplan GG.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1405-1412.e3. doi: 10.1016/j.cgh.2017.02.042. Epub 2017 Mar 23.

37.

Concurrent physician-diagnosed asthma and chronic obstructive pulmonary disease: A population study of prevalence, incidence and mortality.

Kendzerska T, Sadatsafavi M, Aaron SD, To TM, Lougheed MD, FitzGerald JM, Gershon AS; Canadian Respiratory Research Network.

PLoS One. 2017 Mar 16;12(3):e0173830. doi: 10.1371/journal.pone.0173830. eCollection 2017.

38.

A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease.

Zafari Z, Bryan S, Sin DD, Conte T, Khakban R, Sadatsafavi M.

Value Health. 2017 Jan;20(1):152-162. doi: 10.1016/j.jval.2016.08.003. Epub 2016 Oct 10. Review.

39.

The Impact of Statin Drug Use on All-Cause Mortality in Patients With COPD: A Population-Based Cohort Study.

Raymakers AJN, Sadatsafavi M, Sin DD, De Vera MA, Lynd LD.

Chest. 2017 Sep;152(3):486-493. doi: 10.1016/j.chest.2017.02.002. Epub 2017 Feb 12.

PMID:
28202342
40.

Probabilistic Return-on-Investment Analysis of Single-Family Versus Open-Bay Rooms in Neonatal Intensive Care Units-Synthesis and Evaluation of Early Evidence on Nosocomial Infections, Length of Stay, and Direct Cost of Care.

Sadatsafavi H, Niknejad B, Shepley M, Sadatsafavi M.

J Intensive Care Med. 2019 Feb;34(2):115-125. doi: 10.1177/0885066616689774. Epub 2017 Jan 25.

PMID:
28118769
41.

Excess medical costs in patients with asthma and the role of comorbidity.

Chen W, Lynd LD, FitzGerald JM, Marra CA, Balshaw R, To T, Tavakoli H, Sadatsafavi M; Canadian Respiratory Research Network.

Eur Respir J. 2016 Dec;48(6):1584-1592. doi: 10.1183/13993003.01141-2016. Epub 2016 Oct 6.

42.

Has Asthma Medication Use Caught Up With the Evidence?: A 12-Year Population-Based Study of Trends.

Sadatsafavi M, Tavakoli H, Lynd L, FitzGerald JM.

Chest. 2017 Mar;151(3):612-618. doi: 10.1016/j.chest.2016.10.028. Epub 2016 Nov 1.

PMID:
27815152
43.

The Association Between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model.

Sadatsafavi M, Sin DD, Zafari Z, Criner G, Connett JE, Lazarus S, Han M, Martinez F, Albert R.

Am J Epidemiol. 2016 Nov 1;184(9):681-689. Epub 2016 Oct 13.

44.

Biomarker Development in COPD: Moving From P Values to Products to Impact Patient Care.

Hollander Z, DeMarco ML, Sadatsafavi M, McManus BM, Ng RT, Sin DD.

Chest. 2017 Feb;151(2):455-467. doi: 10.1016/j.chest.2016.09.012. Epub 2016 Sep 29. Review.

PMID:
27693595
45.

The impact of a history of asthma on long-term outcomes of people with newly diagnosed chronic obstructive pulmonary disease: A population study.

Kendzerska T, To TM, Aaron SD, Lougheed MD, Sadatsafavi M, FitzGerald JM, Gershon AS; Canadian Respiratory Research Network.

J Allergy Clin Immunol. 2017 Mar;139(3):835-843. doi: 10.1016/j.jaci.2016.06.026. Epub 2016 Sep 15.

PMID:
27641119
46.

The Projected Epidemic of Chronic Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A Population-based Perspective.

Khakban A, Sin DD, FitzGerald JM, McManus BM, Ng R, Hollander Z, Sadatsafavi M.

Am J Respir Crit Care Med. 2017 Feb 1;195(3):287-291. doi: 10.1164/rccm.201606-1162PP. Review. No abstract available.

PMID:
27626508
47.

The impact of comorbidities on productivity loss in asthma patients.

Ehteshami-Afshar S, FitzGerald JM, Carlsten C, Tavakoli H, Rousseau R, Tan WC, Rolf JD, Sadatsafavi M.

Respir Res. 2016 Aug 26;17(1):106. doi: 10.1186/s12931-016-0421-9.

48.

Asthma control and productivity loss in those with work-related asthma: A population-based study.

Wong A, Tavakoli H, Sadatsafavi M, Carlsten C, FitzGerald JM.

J Asthma. 2017 Jun;54(5):537-542. doi: 10.1080/02770903.2016.1220011. Epub 2016 Aug 5.

PMID:
27494107
49.

Individualized prediction of lung-function decline in chronic obstructive pulmonary disease.

Zafari Z, Sin DD, Postma DS, Löfdahl CG, Vonk J, Bryan S, Lam S, Tammemagi CM, Khakban R, Man SFP, Tashkin D, Wise RA, Connett JE, McManus B, Ng R, Hollander Z, Sadatsafavi M.

CMAJ. 2016 Oct 4;188(14):1004-1011. doi: 10.1503/cmaj.151483. Epub 2016 Aug 2.

50.

Ten-year trends in direct costs of asthma: a population-based study.

Tavakoli H, FitzGerald JM, Chen W, Lynd L, Kendzerska T, Aaron S, Gershon A, Marra C, Sadatsafavi M; Canadian Respiratory Research Network.

Allergy. 2017 Feb;72(2):291-299. doi: 10.1111/all.12993. Epub 2016 Aug 24.

PMID:
27455382

Supplemental Content

Loading ...
Support Center